Virtus Biotech Clinical Trials ETF
BBCNYSEARCAVirtus Investment PartnersEquity
As of Oct 16, 2026 close
- Assets (AUM)
- $42.32M
- Expense ratio
- 0.65%
- Dividend yield
- 1.59%
- Holdings
- 130
- 52-week range
- $28.73$56.18
- Volume (live)
- -
- Avg. volume (3M)
- 22.28K
BBC ETF: Virtus Biotech Clinical Trials ETF - Price, Holdings & Analysis
Virtus Biotech Clinical Trials ETF Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $39.05 - $40.30 |
|---|---|
| 52-Week High | $56.18 |
| 52-Week Low | $28.73 |
| Open | $40.30 |
| Volume (last close) | 85.40K |
| Average Volume (3M) | 22.28K |
| 1 Day Change | +2.51% |
|---|---|
| 1 Month Change | −16.42% |
| 6 Month Change | −13.20% |
| YTD Change | +9.38% |
| 1 Year Change | +36.71% |
| 5 Year Change | −9.01% |
| 10 Year Change | +109.68% |
| Annual Dividend | $0.66 |
|---|---|
| Dividend Yield | 1.59% |
| Last Dividend Ex-Date | Dec 22, 2025 |
| Dividend Growth YoY | +173.70% |
| Years Dividend Growth | 2 |
| Assets (AUM) | $42.32M |
|---|---|
| Expense Ratio | 0.65% |
| Total Holdings | 130 |
| Inception Date | Dec 15, 2014 |
| 50-Day MA | $49.71 |
|---|---|
| 200-Day MA | $45.45 |
| RSI | 24.14 |
| Stochastic %K | -6.98 |
| Stochastic %D | 2.16 |
Source: Exchange price data and fund disclosures. Data as of Oct 16, 2026. Data sources and methodology
BBC at a Glance
Virtus Biotech Clinical Trials ETF (BBC) is an equity ETF from Virtus Investment Partners, launched in December 2014. It manages $42.32M in assets and charges a 0.65% expense ratio, about $65 a year per $10,000 invested.
As of its Oct 4, 2026 holdings, it holds 130 positions. The largest are Kodiak Sciences Inc. (KOD, 2.08%), AbCellera Biologics Inc. (ABCL, 1.97%) and Amylyx Pharmaceuticals Inc. Common Stock (AMLX, 1.59%). The top 10 holdings make up 14.5% of the fund. By sector it leans toward Healthcare (100.0%). Its largest country exposures are United States (89.3%), United Kingdom (2.9%) and Canada (2.4%).
It pays distributions yielding 1.59% at the Oct 16, 2026 close, $0.66 per share over the trailing 12 months. As of the Oct 16, 2026 close, the share price is up 36.7% over one year, down 9.0% over five years and up 109.7% over ten years (price change, excluding distributions).
Frequently Asked Questions About Virtus Biotech Clinical Trials ETF
What is the current price of BBC?
The latest BBC price is $39.12 (Oct 16, 2026 close). The 52-week range is $28.73–$56.18. The share price is up 36.7% over the past year (price change, excluding distributions).
What is the expense ratio for BBC?
BBC's annual expense ratio is 0.65%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does BBC pay dividends?
Yes, BBC pays a 1.59% dividend yield (trailing 12 months, at the Oct 16, 2026 close). The most recent ex-dividend date was December 22, 2025. View full dividend history in the Dividends section.
What are the top holdings of BBC?
As of Oct 4, 2026, BBC's largest holdings are Kodiak Sciences Inc. (2.1%), AbCellera Biologics Inc. (2.0%), Amylyx Pharmaceuticals Inc. Common Stock (1.6%) (combined weight: 5.6%). The fund holds 130 total positions. View the complete portfolio breakdown in the Holdings section.
How does BBC compare to similar ETFs?
Compare BBC (0.65% expense ratio, $42M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.